Pulmatrix, Inc. (NASDAQ:PULM – Get Free Report)’s share price crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.59 and traded as low as $1.23. Pulmatrix shares last traded at $1.27, with a volume of 17,598 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.
View Our Latest Stock Analysis on PULM
Pulmatrix Trading Up 1.6%
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) EPS for the quarter.
Institutional Investors Weigh In On Pulmatrix
An institutional investor recently bought a new position in Pulmatrix stock. DRW Securities LLC purchased a new stake in Pulmatrix, Inc. (NASDAQ:PULM – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors and hedge funds own 11.84% of the company’s stock.
Pulmatrix Company Profile
Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.
Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).
Read More
- Five stocks we like better than Pulmatrix
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
